New developed antibody
Educational only: videos on MedicalVideos.com are for general information and are not medical advice. Always consult your own doctor about your health.
A new report analyzing FDA-approved monoclonal antibodies (mAbs) produced by a select group of leading biotechnology companies shows that clinical development times – specifically the duration of Phase II and Phase III trials – are lengthening, while FDA review times have remained constant. The average time from investigational new drug (IND) filing to market was 6.7 years for 11 mABs approved between 1994 and 2003 but shot up to 8.3 years for 12 mAbs approved between 2004 and March 9, 2011, according to Deloitte Recap LLC’s analysis, Therapeutic Monoclonal Antibodies – Insights, Strategies and Data.
Video Overview
This video presents “New developed antibody” — A new report analyzing FDA-approved monoclonal antibodies (mAbs) produced by a select group of leading biotechnology companies shows that clinical development times – specifically the duration of Phase II and Phase III trials – are. Whether you are preparing for a procedure, studying the technique, or learning how a condition is assessed, the recording shows the process as it is performed in practice.
From our General Medical Videos collection: General medical videos: a wide collection of procedures, conditions and explainers from every specialty — free medical education since 2007. Browse all General Medical Videos videos →
Educational content only — not a substitute for professional medical advice.
Medical Videos
Free medical and surgery videos for patients, students and professionals — trusted since 2007.
Founded by Dr. Mohamed Ibrahim, MD, PhD — physician-scientist.
Follow us on Facebook · Instagram
SORT BY-
Top Comments
-
Latest comments